Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

122
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
122

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON.

Ophthalmology and therapy·2026
Same author

Diabetic retinal disease: Five trials to watch.

Med (New York, N.Y.)·2026
Same author

Long term evaluation of the safety and efficacy of local cooling anesthesia during intravitreal injections: The COOL-2 Trial.

PloS one·2026
Same author

Visual and Anatomic Outcomes of Faricimab in Naïve Neovascular Age-Related Macular Degeneration with Subretinal Hemorrhage: A Multi-Centre Retrospective Analysis.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Reduction in Pigment Epithelial Detachment Thickness with Faricimab versus Aflibercept 2 mg during Head-to-Head Dosing in TENAYA/LUCERNE.

Ophthalmology science·2026
Same author

An update on the port delivery system with ranibizumab for retinal diseases.

Expert opinion on drug delivery·2026

Related Experiment Video

Updated: Aug 25, 2025

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery
07:45

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Published on: March 4, 2021

3.4K

Macular Telangiectasia Type 2: A Comprehensive Review.

Kiran Chandra Kedarisetti1, Raja Narayanan1,2, Michael W Stewart3

  • 1Anant Bajaj Retina Institute, LV Prasad Eye Institute, Hyderabad, Telangana, India.

Clinical Ophthalmology (Auckland, N.Z.)
|October 14, 2022
PubMed
Summary

Macular telangiectasia Type 2 (MacTel) is a progressive vision impairment. Emerging evidence points to Muller cell neurodegeneration, not just vascular issues, as the cause, impacting quality of life.

Keywords:
CNTFMacTelciliary neurotrophic factormacular telangiectasia type 2

More Related Videos

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.2K
Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
12:28

Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies

Published on: March 12, 2022

3.7K

Related Experiment Videos

Last Updated: Aug 25, 2025

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery
07:45

Toxicity Screens in Human Retinal Organoids for Pharmaceutical Discovery

Published on: March 4, 2021

3.4K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.2K
Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
12:28

Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies

Published on: March 12, 2022

3.7K

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Genetics

Background:

  • Macular telangiectasia Type 2 (MacTel) is a progressive condition affecting vision.
  • Previously viewed as vascular, MacTel now shows evidence of neurodegeneration, particularly Muller cell involvement.
  • Vision loss in advanced MacTel stems from retinal pigment epithelium (RPE) hyperplasia and subretinal neovascularization (SNV).

Purpose of the Study:

  • To review the pathophysiology of Macular telangiectasia Type 2.
  • To outline the clinical features and diagnostic imaging for MacTel.
  • To discuss current and emerging treatment options for MacTel.

Main Methods:

  • Literature review of MacTel pathophysiology, clinical presentation, diagnostics, and treatments.
  • Analysis of recent evidence suggesting neurodegenerative origins.
  • Synthesis of information on therapeutic interventions.

Main Results:

  • MacTel pathophysiology involves Muller cell dysfunction and RPE changes.
  • Diagnostic imaging plays a crucial role in identifying MacTel.
  • Both neurotrophic factors and anti-VEGF therapies show potential in managing MacTel progression.

Conclusions:

  • MacTel is increasingly understood as a neurodegenerative disease.
  • Early diagnosis and targeted therapies are key to managing MacTel.
  • Further research into MacTel's neurodegenerative aspects may yield novel treatments.